Moxifloxacin: An Alternative to Ethambutol for the Treatment of Presumed Ocular Tuberculosis

References

• WHO. Global Tuberculosis Report. Geneva, Switzerland: World Health Organisation; 2013. Available from: www.who.int/tb/publications/global_report/en/
   Google Scholar
• Lou SM, Larkin KL, Winthrop K, et al. Lack of consensus in the diagnosis and treatment for ocular tuberculosis among uveitis specialists. Published Online First: 14 July 2014. informahealthcare.com/doi/abs/10.3109/09273948.2014.926936 [last accessed 19 Jul 2014]
   Google Scholar
• WHO. Treatment of Tuberculosis: Guidelines, 4th edition. WHO 2009;WHO/HTM/TB/2009.4
   Google Scholar
• Caminero JA. Guidelines for clinical and operational management of drug-resistant tuberculosis 2013. Int Union Against Tuberc Lung Dis. 2013
   Google Scholar
• National Collaborating Centre for Chronic Conditions (UK); Centre for Clinical Practice at NICE (UK). Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. 2011
   Google Scholar
• CDC. Treatment of tuberculosis. MMWR Recomm Rep. 2003;52:1–77. www.ncbi.nlm.nih.gov/pubmed/12836625 [last accessed 28 Sep 2014]
   Google Scholar
• National Institute for Health and Clinical Excellence. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. NICE 2011;NICE Clinical Guideline 117. guidance.nice.org.uk/CG117
   Google Scholar
• Tuberculosis in the UK – 2013 report. Public Health England 2013. www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139689583
   Google Scholar
• PHE. Tuberculosis in the UK 2014 report. 2014
   Google Scholar
• London HPA, Bulletin S. London: Tuberculosis for London's health professionals. 2013;1–17
   Google Scholar
• Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010;59:1–25. www.ncbi.nlm.nih.gov/pubmed/20577159 [last accessed 31 Aug 2014]
   Google Scholar
• Gupta V, Gupta A, Rao NA. Intraocular tuberculosis—an update. Surv Ophthalmol. 52:561–87. doi:10.1016/j.survophthal.2007.08.015
   PubMed Web of Science ®Google Scholar
• Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nature Rev Microbiol. 2014;12:159–67
   PubMed Web of Science ®Google Scholar
• Hand WL, Corwin RW, Steinberg TH, Grossman GD. Uptake of antibiotics by human alveolar macrophages. Am Rev Respir Dis. 1984;129:933–7
   PubMed Web of Science ®Google Scholar
• Ezer N, Benedetti A, Darvish-Zargar M, et al. Incidence of ethambutol-related visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis. 2013;17:447–55
   PubMed Web of Science ®Google Scholar
• Falzon D, Jaramillo E, Schünemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J. 2011;38:516–28
   PubMed Web of Science ®Google Scholar
• Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4:e6914. doi:10.1371/journal.pone.0006914
   PubMed Web of Science ®Google Scholar
• Conde MB, Efron A, Loredo C, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet. 2009;373:1183–9
   PubMed Web of Science ®Google Scholar
• Ziglam HM, Baldwin DR, Daniels I, et al. Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600-mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 2002;50:1011–15
   PubMed Web of Science ®Google Scholar
• Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400-mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother. 1999;44:835–8
   PubMed Web of Science ®Google Scholar
• Pranger AD, van Altena R, Aarnoutse RE, et al. Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience. Eur Respir J. 2011;38:888–94
   PubMed Web of Science ®Google Scholar
• Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13:27–35
   PubMed Web of Science ®Google Scholar
• Potter JL, Capstick T, Ricketts WM, et al. A UK-based resource to support the monitoring and safe use of anti-TB drugs and second-line treatment of multidrug-resistant TB. Thorax. Published Online First: 13 June 2014. doi:10.1136/thoraxjnl-2014-205278
   Google Scholar
• Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev. 2013;6:CD004795. doi:10.1002/14651858.CD004795.pub4
   Google Scholar
• Pilheu JA, Maglio F, Cetrangolo R, et al. Concentrations of ethambutol in the cerebrospinal fluid after oral administration. Tubercle. 1971;52:117–22. Available from: www.ncbi.nlm.nih.gov/pubmed/5560732 [last accessed 18 Sep 2014]
   Google Scholar
• Alffenaar JWC, van Altena R, Bökkerink HJ, et al. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin Infect Dis. 2009;49:1080–2. doi:10.1086/605576
   PubMed Web of Science ®Google Scholar
• Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2014; 140907080012008. doi:10.1056/NEJMoa1407426
   Web of Science ®Google Scholar
• Gupta V, Bansal R, Gupta A. Continuous progression of tubercular serpiginous-like choroiditis after initiating antituberculosis treatment. Am J Ophthalmol. 2011;152:857–63 e852
   PubMed Web of Science ®Google Scholar